Metabolic Activity Assessment by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients after COVID-19 Vaccination

Shalata, Walid; Levin, Daniel; Fridman, Janna; Макаров, В. В.; Iraqi, Muhammed; Golosky, Mitchell; Rouvinov, Keren; Kian, Waleed; Yakobson, Alexander

doi:10.3390/curroncol29020084

Cited by 3 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiologists and pathologists play a pivotal role in resolving this diagnostic ambiguity. Determining the distribution pattern of metastatic lesions, recognizing morphological similarities between sites of metastases, and, in more complex cases, conducting arterial and venous phase studies contribute to establishing the diagnosis of metastasis at unconventional locations [52]. In instances where the metastasis is solitary or where the nature of the lesion is challenging to ascertain, an additional tissue biopsy from the uncommon site may be necessary to confirm the presence of metastatic disease.…”

Section: Discussionmentioning

confidence: 99%

Unexpected and Rare Sites of Metastasis in Oncologic Patients

Shalata,

Abu Jama,

Abu Salman

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Case studies of rare oncologic metastases are an important source of clinical data for health care professionals and researchers. While infrequent, the knowledge base and clinical recommendations derived from such cases aid in advancements in the field. As such, we aim to add five cases to the growing body of literature. The first two male patients, aged 69 and 73, were diagnosed with colon adenocarcinoma, suspected to be a second primary prostate carcinoma, following positron emission tomography-computer tomography (PET-CT). This suspicion was ruled out by prostatectomy and histopathological investigations, which instead found adenocarcinoma of colonic origin. The next two male patients, ages 63 and 68, were diagnosed, respectively, with metastatic pancreatic adenocarcinoma with cardiac metastases and metastatic melanoma with distant metastases to the pancreas. The final patient was a 73-year-old male diagnosed with metastatic breast cancer after a radiological investigation of suspected renal cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Unexpected and Rare Sites of Metastasis in Oncologic Patients

Shalata,

Abu Jama,

Abu Salman

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…A recent study by Cohen et al [ 18 ] showed that the incidence of lymphadenopathy after BNT162b2 mRNA COVID-19 vaccine identified by 18 F-FDG PET-CT, was up to 53.9% after the booster shot. Besides axillary adenopathies, which are easily visualized by US, it was discussed in various articles that the strong immune response to vaccines is observed on 18 F-FDG PET-CT as an increased uptake in different and multiple lymph node territories, such as the mediastinum, the neck, the supraclavicular fossae and even the abdomen, following a vaccination in the deltoid muscle [ 21 , 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

Understanding COVID Vaccination and Its Implication in Cancer Patients’ Imaging of Lymph Nodes by PET-CT

et al. 2022

View full text Add to dashboard Cite

(1) Background: The appearance of enlarged lymph nodes on imaging adds another layer of complexity to the differential diagnosis of disease progression versus immune response to COVID-19 vaccines. Our aim was to find an optimal timing between the vaccination and the PET-CT scan. (2) Methods: 25 cancer patients with 18F-FDG PET-CT evaluations and a history of COVID-19 vaccination between September 2021 and December 2021 were retrospectively analyzed to characterize the lymph nodes related to the time interval from COVID vaccination. (3) Results: All patients presented one or more adenopathies localized in the ipsilateral axilla (96%), ipsilateral cervical area (20%), ipsilateral retropectoral (20%) and pulmonary hilum (8%). The median value of SUVmax was 3.5 ± 0.5. There was a significant indirect correlation between SUVmax and the time passed between the vaccination and the PET CT (Pearson Correlation r = −0.54, p = 0.005). There was no significant difference (p = 0.19) in the SUVmax value in patients receiving Moderna mRNA-1273 vaccine vs. BNT162b2 mRNA Pfizer vaccine. (4) Conclusions: Lymph node enlargement is commonly seen in patients post-vaccination for COVID-19 and must be differentiated from disease progression. The data from our study strongly suggests that the minimum interval of time between an mRNA vaccine and a PET-CT should be more than six weeks.

show abstract

“…Nevertheless, myocarditis associated with DRESS is associated with a similarly high mortality rate, approximately 40% [72]. When comparing the rarity of Immune Checkpoint Inhibitor-Induced Myocarditis to COVID-19-associated myocarditis, this discrepancy may stem from challenges related to misclassification and the intricate diagnosis of cardiac events triggered by ICIs, or other rare and unexpected adverse events related to the COVID-19 vaccine, particularly amid the ongoing COVID-19 pandemic [73][74][75][76][77][78]. A systematic review encompassing 43 articles, ultimately identified 51 patients with COVID-19-associated myocarditis based on clinical diagnosis.…”

Section: Managementmentioning

confidence: 99%

Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review

Shalata,

Attal,

Shhadi

et al. 2023

Medicina

Self Cite

View full text Add to dashboard Cite

Many different types of cancer can be treated with immunotherapy drugs called immune checkpoint inhibitors (ICIs). These drugs have altered the landscape of cancer treatment options since they function by triggering a stronger immune response to malignancy. As expected, ICIs’ modification of immune regulatory controls leads to a wide range of organ/gland-specific immune-related side effects. These adverse effects are uncommonly deadly and typically improve by discontinuing treatment or administering corticosteroid drugs. As a result of a number of factors—including a lack of specificity in the clinical presentation, the possibility of overlap with other cardiovascular and general medical illnesses, difficulties in diagnosis, and a general lack of awareness—the true incidence of ICI-associated myocarditis is likely underestimated. Currently, protocols for the surveillance, diagnosis, or treatment of this condition are unclear. Several questions remain unanswered, such as how to best screen for this rare toxin, what tests should be run on patients who are suspected of having it, how to treat myocarditis once it has developed, and who is at most risk. In this article, we provide a case study of ICI-associated myocarditis and explain its key characteristics and treatment options.

show abstract

Metabolic Activity Assessment by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients after COVID-19 Vaccination

Cited by 3 publications

References 15 publications

Unexpected and Rare Sites of Metastasis in Oncologic Patients

Unexpected and Rare Sites of Metastasis in Oncologic Patients

Understanding COVID Vaccination and Its Implication in Cancer Patients’ Imaging of Lymph Nodes by PET-CT

Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review

Contact Info

Product

Resources

About